ASH Annual Meeting and Exposition

Findings from a retrospective analysis identified Black race as an independent predictor of inferior survival outcomes with intensive chemotherapy in AML.

Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.

In the CaDAnCe-101 study, BGB-16673 was tolerable, effective, and showed sustained disease control in high-risk, heavily pretreated, relapsed/refractory CLL/SLL.

Zanubrutinib plus R-CHOP produced a high ORR and CR rate in untreated DLBCL with certain gene expression.

Thirty percent of families of pediatric patients with ALL receiving chemotherapy experienced catastrophic financial toxicities.

Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.

Fixed-duration venetoclax combinations delivered PFS comparable with continuous ibrutinib in the phase 3 CLL17 trial.

The phase 2 EndRAD study found that removing TBI from conditioning did not compromise efficacy in pediatric or young adult patients with B-cell ALL.

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

Ahead of the 2025 ASH Annual Meeting, OncLive spoke with experts in CLL care to preview the most anticipated meeting abstracts.

Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.

Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.

Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.

Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.

Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.

IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.

NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.

Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Isa-RVd given as induction treatment without consolidation led to a 30% reduction in the risk of disease progression or death vs RVd in multiple myeloma.

Pirtobrutinib improved progression-free survival in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Results of the EA4151/BMT-CTN 1601 trial showed similar progression-free and overall outcomes with the addition of autologous transplant to rituximab in mantle cell lymphoma.

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.

First-line pirtobrutinib plus venetoclax and obinutuzumab generated high uMRD6 remission rates among patients with chronic lymphocytic leukemia.

Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

Rachel E. Rau, MD, discusses findings that show blinatumomab plus chemotherapy improves DFS in newly diagnosed B-ALL.

Timothy S. Fenske, MD, MS, shares outcomes from the phase 3 ECOG-ACRIN EA4151 trial of patients with mantle cell lymphoma after first MRD-negative CR.

Axi-cel sustained long-term efficacy in relapsed/refractory follicular lymphoma and marginal zone lymphoma.